Company
Oncimmune Holdings PLC
LON:ONC
Oncimmune Holdings PLC is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
139 stories · page 2 of 7
Oncimmune says 2023 will be an 'inflexion year' for the business
"The commercial pipeline has grown well under our new chief business officer who was appointed in September 2021,” said CEO Adam Hill
Oncimmune appoints new chair, updates on trading
“Medicare coverage will also ensure physicians have access to the NodifyCDT lung nodule test"
Oncimmune receives 2022 Queen's Award for Enterprise
The award recognises Oncimmune as a leading developer of applied immunodiagnostics for the early detection of disease
Oncimmune lands new contracts for its ImmunoINSIGHTS services
It has inked deals with two US drug developers to provide scientific feedback on the treatments they are developing
Oncimmune lands follow-on Covid study contract
The unnamed customer is a “world-leading” medical research group based in the US, investors were told
Oncimmune Holdings announces its third deal of the week
This latest agreement is with an unnamed top ten pharmaceutical company
Oncimmune inks second partnership deal in two days
It is teaming up with Synexa Life Sciences to deliver autoantibody screening
Oncimmune teams up with health company owned by Google parent in long Covid collaboration
The AIM-listed immunodiagnostics firm is teaming up with Verily Life Sciences
Oncimmune lung cancer diagnostic wins green light from second Spanish regional health authority
The latest news is seen as an important development for the company's distributor, Sabartech
Oncimmune Holdings' ImmunoINSIGHTS operation lands contract profile patients with skin condition
It has been given the task of profiling people with chronic idiopathic urticaria (CIU), a skin condition that is also sometimes referred to as ‘hives’
Oncimmune says ImmunoINSIGHTS pharma services business delivered a record quarter
“The potential for ImmunoINSIGHTS has been validated by my network of commercial professionals and pharma and biotech contacts," said the company's chief business officer, Cameron Barnard
Archive
FIVE at FIVE: Legal German weed, money on the WIND, the Footsie, Hochschild keeps its mines – and the earthly benefits of space investing
Here’s Proactive’s round-up of the day’s news with helpful links taking you our up-to-the-minute news analysis.
Proactive news headlines: Gaming Realms, XLMedia, Greencoat UK Wind ...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune sees significant momentum driven by ImmunoINSIGHTS service
The autoantibody profiling service developed a pipeline of over 160 commercial opportunities last financial year and continues to secure follow-on contracts with customers of strategic importance
Oncimmune signs agreement with big pharma group for autoimmune diseases profiling
Oncimmune will utilise its autoimmune disease characterisation panel to explore the profiles of patients with four diseases
Oncimmune hails three-year follow-up data from landmark early detection lung cancer trial
Readers of the peer-reviewed article were told late-stage cancers and deaths were lower in the group of patients assessed using the company’s diagnostic